nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—Mycophenolic acid—psoriasis	0.104	0.137	CbGbCtD
Ezetimibe—UGT1A1—Mycophenolic acid—psoriasis	0.0895	0.118	CbGbCtD
Ezetimibe—UGT2B7—Mycophenolate mofetil—psoriasis	0.0579	0.0763	CbGbCtD
Ezetimibe—ABCC3—Cyclosporine—psoriasis	0.0507	0.0669	CbGbCtD
Ezetimibe—UGT1A1—Mycophenolate mofetil—psoriasis	0.05	0.066	CbGbCtD
Ezetimibe—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0346	0.0457	CbGbCtD
Ezetimibe—ABCC2—Mycophenolate mofetil—psoriasis	0.0304	0.0401	CbGbCtD
Ezetimibe—ABCG2—Mycophenolate mofetil—psoriasis	0.0275	0.0363	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—psoriasis	0.0269	0.0354	CbGbCtD
Ezetimibe—SLCO1B1—Cyclosporine—psoriasis	0.0262	0.0346	CbGbCtD
Ezetimibe—ABCC2—Cyclosporine—psoriasis	0.0231	0.0304	CbGbCtD
Ezetimibe—ABCG2—Hydrocortisone—psoriasis	0.0221	0.0291	CbGbCtD
Ezetimibe—ABCG2—Cyclosporine—psoriasis	0.0208	0.0275	CbGbCtD
Ezetimibe—ABCC2—Dexamethasone—psoriasis	0.0152	0.02	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—psoriasis	0.0139	0.0183	CbGbCtD
Ezetimibe—ABCG2—Dexamethasone—psoriasis	0.0137	0.0181	CbGbCtD
Ezetimibe—CYP3A4—Calcitriol—psoriasis	0.0133	0.0175	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—psoriasis	0.0122	0.0161	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—psoriasis	0.011	0.0146	CbGbCtD
Ezetimibe—CYP3A4—Methoxsalen—psoriasis	0.0103	0.0136	CbGbCtD
Ezetimibe—ABCB1—Mycophenolate mofetil—psoriasis	0.00992	0.0131	CbGbCtD
Ezetimibe—ABCB1—Betamethasone—psoriasis	0.00851	0.0112	CbGbCtD
Ezetimibe—ABCB1—Prednisolone—psoriasis	0.0084	0.0111	CbGbCtD
Ezetimibe—ABCB1—Hydrocortisone—psoriasis	0.00796	0.0105	CbGbCtD
Ezetimibe—ABCB1—Prednisone—psoriasis	0.00793	0.0105	CbGbCtD
Ezetimibe—ABCB1—Cyclosporine—psoriasis	0.00752	0.00992	CbGbCtD
Ezetimibe—CYP3A4—Cholecalciferol—psoriasis	0.00685	0.00904	CbGbCtD
Ezetimibe—CYP3A4—Triamcinolone—psoriasis	0.00594	0.00784	CbGbCtD
Ezetimibe—CYP3A4—Mycophenolate mofetil—psoriasis	0.00594	0.00784	CbGbCtD
Ezetimibe—ANPEP—Metabolism of Angiotensinogen to Angiotensins—REN—psoriasis	0.00584	0.118	CbGpPWpGaD
Ezetimibe—CYP3A4—Betamethasone—psoriasis	0.0051	0.00673	CbGbCtD
Ezetimibe—CYP3A4—Prednisolone—psoriasis	0.00503	0.00664	CbGbCtD
Ezetimibe—ABCB1—Dexamethasone—psoriasis	0.00495	0.00653	CbGbCtD
Ezetimibe—CYP3A4—Hydrocortisone—psoriasis	0.00477	0.00629	CbGbCtD
Ezetimibe—CYP3A4—Prednisone—psoriasis	0.00475	0.00627	CbGbCtD
Ezetimibe—CYP3A4—Cyclosporine—psoriasis	0.0045	0.00594	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—psoriasis	0.00398	0.00525	CbGbCtD
Ezetimibe—ANPEP—Metabolism of Angiotensinogen to Angiotensins—ACE—psoriasis	0.00364	0.0733	CbGpPWpGaD
Ezetimibe—CYP3A4—Dexamethasone—psoriasis	0.00297	0.00391	CbGbCtD
Ezetimibe—SOAT1—Statin Pathway—APOE—psoriasis	0.00288	0.058	CbGpPWpGaD
Ezetimibe—ABCG5—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.0016	0.0322	CbGpPWpGaD
Ezetimibe—ANPEP—Peptide hormone metabolism—REN—psoriasis	0.00154	0.0309	CbGpPWpGaD
Ezetimibe—ABCG8—Statin Pathway—APOE—psoriasis	0.00151	0.0305	CbGpPWpGaD
Ezetimibe—ABCG5—Statin Pathway—APOE—psoriasis	0.00146	0.0293	CbGpPWpGaD
Ezetimibe—NPC1L1—Lipid and lipoprotein metabolism—APOE—psoriasis	0.00129	0.026	CbGpPWpGaD
Ezetimibe—ABCG5—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00112	0.0225	CbGpPWpGaD
Ezetimibe—ABCG8—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000979	0.0197	CbGpPWpGaD
Ezetimibe—ANPEP—Peptide hormone metabolism—ACE—psoriasis	0.000958	0.0193	CbGpPWpGaD
Ezetimibe—ABCG5—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000942	0.019	CbGpPWpGaD
Ezetimibe—UGT2B15—Biological oxidations—CYP2S1—psoriasis	0.000879	0.0177	CbGpPWpGaD
Ezetimibe—ABCC3—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000744	0.015	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL22—psoriasis	0.00067	0.0135	CbGpPWpGaD
Ezetimibe—ANPEP—Peptide hormone metabolism—LEP—psoriasis	0.000595	0.012	CbGpPWpGaD
Ezetimibe—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000589	0.0119	CbGpPWpGaD
Ezetimibe—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000554	0.0111	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000525	0.0106	CbGpPWpGaD
Ezetimibe—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000514	0.0103	CbGpPWpGaD
Ezetimibe—UGT1A3—Biological oxidations—CYP2S1—psoriasis	0.000471	0.00948	CbGpPWpGaD
Ezetimibe—UGT1A3—Metapathway biotransformation—CYP2S1—psoriasis	0.000464	0.00935	CbGpPWpGaD
Ezetimibe—ABCG2—Iron uptake and transport—CP—psoriasis	0.000428	0.00862	CbGpPWpGaD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000427	0.00859	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—CD4—psoriasis	0.000415	0.00835	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—NDUFA5—psoriasis	0.000414	0.00834	CbGpPWpGaD
Ezetimibe—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.0004	0.00806	CbGpPWpGaD
Ezetimibe—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000395	0.00795	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000386	0.00777	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000362	0.0073	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—CYP2S1—psoriasis	0.000352	0.00709	CbGpPWpGaD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000339	0.00681	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—CYP2S1—psoriasis	0.000325	0.00655	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000321	0.00646	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—NDUFA5—psoriasis	0.000314	0.00632	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000304	0.00612	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—NDUFA5—psoriasis	0.000302	0.00608	CbGpPWpGaD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000298	0.00599	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000293	0.00589	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—CP—psoriasis	0.000292	0.00587	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—REN—psoriasis	0.00029	0.00583	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000282	0.00567	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—CP—psoriasis	0.000281	0.00565	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—CARM1—psoriasis	0.000278	0.0056	CbGpPWpGaD
Ezetimibe—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000277	0.00558	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—CARM1—psoriasis	0.000268	0.00539	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CYP2S1—psoriasis	0.000267	0.00537	CbGpPWpGaD
Ezetimibe—UGT1A3—NRF2 pathway—TGFA—psoriasis	0.000262	0.00528	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CYP2S1—psoriasis	0.000257	0.00517	CbGpPWpGaD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000236	0.00475	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000226	0.00454	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000223	0.00449	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000223	0.00449	CbGpPWpGaD
Ezetimibe—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000214	0.0043	CbGpPWpGaD
Ezetimibe—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000211	0.00424	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000195	0.00392	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000185	0.00371	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—TGFA—psoriasis	0.000181	0.00365	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—ACE—psoriasis	0.000181	0.00364	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—NDUFA5—psoriasis	0.000177	0.00356	CbGpPWpGaD
Ezetimibe—ABCC2—NRF2 pathway—TGFA—psoriasis	0.000177	0.00356	CbGpPWpGaD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000173	0.00348	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—CARM1—psoriasis	0.000172	0.00346	CbGpPWpGaD
Ezetimibe—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000171	0.00344	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000164	0.00331	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000161	0.00324	CbGpPWpGaD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000159	0.0032	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000156	0.00314	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CYP2S1—psoriasis	0.00015	0.00303	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000146	0.00294	CbGpPWpGaD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	0.000143	0.00287	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.00014	0.00281	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000139	0.00279	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000135	0.00271	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000135	0.00271	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CARM1—psoriasis	0.00013	0.00262	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000129	0.0026	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000127	0.00256	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000127	0.00255	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL13—psoriasis	0.000126	0.00254	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CARM1—psoriasis	0.000125	0.00253	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000122	0.00245	CbGpPWpGaD
Ezetimibe—Angioedema—Betamethasone—psoriasis	0.000121	0.000628	CcSEcCtD
Ezetimibe—Angioedema—Dexamethasone—psoriasis	0.000121	0.000628	CcSEcCtD
Ezetimibe—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00012	0.000627	CcSEcCtD
Ezetimibe—Diarrhoea—Mycophenolic acid—psoriasis	0.00012	0.000625	CcSEcCtD
Ezetimibe—Angiopathy—Prednisone—psoriasis	0.00012	0.000624	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00012	0.000622	CcSEcCtD
Ezetimibe—Immune system disorder—Prednisone—psoriasis	0.000119	0.000621	CcSEcCtD
Ezetimibe—Malaise—Betamethasone—psoriasis	0.000119	0.00062	CcSEcCtD
Ezetimibe—Malaise—Dexamethasone—psoriasis	0.000119	0.00062	CcSEcCtD
Ezetimibe—Anaphylactic shock—Triamcinolone—psoriasis	0.000119	0.000618	CcSEcCtD
Ezetimibe—Constipation—Mycophenolate mofetil—psoriasis	0.000118	0.000616	CcSEcCtD
Ezetimibe—Pain—Mycophenolate mofetil—psoriasis	0.000118	0.000616	CcSEcCtD
Ezetimibe—Infection—Triamcinolone—psoriasis	0.000118	0.000614	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000117	0.00236	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Cyclosporine—psoriasis	0.000117	0.000609	CcSEcCtD
Ezetimibe—Insomnia—Prednisolone—psoriasis	0.000117	0.000608	CcSEcCtD
Ezetimibe—Alopecia—Prednisone—psoriasis	0.000117	0.000608	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Methotrexate—psoriasis	0.000116	0.000606	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Cyclosporine—psoriasis	0.000116	0.000604	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000116	0.00234	CbGpPWpGaD
Ezetimibe—Dizziness—Mycophenolic acid—psoriasis	0.000116	0.000604	CcSEcCtD
Ezetimibe—Paraesthesia—Prednisolone—psoriasis	0.000116	0.000604	CcSEcCtD
Ezetimibe—Mental disorder—Prednisone—psoriasis	0.000116	0.000603	CcSEcCtD
Ezetimibe—Erythema—Prednisone—psoriasis	0.000115	0.000599	CcSEcCtD
Ezetimibe—Malnutrition—Prednisone—psoriasis	0.000115	0.000599	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000115	0.000598	CcSEcCtD
Ezetimibe—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000114	0.000594	CcSEcCtD
Ezetimibe—Insomnia—Hydrocortisone—psoriasis	0.000114	0.000594	CcSEcCtD
Ezetimibe—Hypertension—Dexamethasone—psoriasis	0.000114	0.000594	CcSEcCtD
Ezetimibe—Hypertension—Betamethasone—psoriasis	0.000114	0.000594	CcSEcCtD
Ezetimibe—Paraesthesia—Hydrocortisone—psoriasis	0.000113	0.00059	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000113	0.000589	CcSEcCtD
Ezetimibe—Urticaria—Cyclosporine—psoriasis	0.000113	0.000587	CcSEcCtD
Ezetimibe—Myalgia—Betamethasone—psoriasis	0.000112	0.000585	CcSEcCtD
Ezetimibe—Myalgia—Dexamethasone—psoriasis	0.000112	0.000585	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—LEP—psoriasis	0.000112	0.00226	CbGpPWpGaD
Ezetimibe—Abdominal pain—Cyclosporine—psoriasis	0.000112	0.000584	CcSEcCtD
Ezetimibe—Body temperature increased—Cyclosporine—psoriasis	0.000112	0.000584	CcSEcCtD
Ezetimibe—Vomiting—Mycophenolic acid—psoriasis	0.000112	0.000581	CcSEcCtD
Ezetimibe—Discomfort—Dexamethasone—psoriasis	0.000111	0.000578	CcSEcCtD
Ezetimibe—Discomfort—Betamethasone—psoriasis	0.000111	0.000578	CcSEcCtD
Ezetimibe—Dyspepsia—Hydrocortisone—psoriasis	0.000111	0.000578	CcSEcCtD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000111	0.00223	CbGpPWpGaD
Ezetimibe—Rash—Mycophenolic acid—psoriasis	0.000111	0.000576	CcSEcCtD
Ezetimibe—Dermatitis—Mycophenolic acid—psoriasis	0.000111	0.000575	CcSEcCtD
Ezetimibe—Pain—Prednisolone—psoriasis	0.00011	0.000575	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—psoriasis	0.00011	0.000575	CcSEcCtD
Ezetimibe—Urticaria—Mycophenolate mofetil—psoriasis	0.00011	0.000573	CcSEcCtD
Ezetimibe—Headache—Mycophenolic acid—psoriasis	0.00011	0.000572	CcSEcCtD
Ezetimibe—Decreased appetite—Hydrocortisone—psoriasis	0.00011	0.000571	CcSEcCtD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	0.00011	0.00221	CbGpPWpGaD
Ezetimibe—Pharyngitis—Methotrexate—psoriasis	0.00011	0.00057	CcSEcCtD
Ezetimibe—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000109	0.00057	CcSEcCtD
Ezetimibe—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000109	0.00057	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000109	0.000567	CcSEcCtD
Ezetimibe—Fatigue—Hydrocortisone—psoriasis	0.000109	0.000566	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000108	0.000563	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000108	0.00217	CbGpPWpGaD
Ezetimibe—Pain—Hydrocortisone—psoriasis	0.000108	0.000562	CcSEcCtD
Ezetimibe—Anaphylactic shock—Dexamethasone—psoriasis	0.000108	0.000561	CcSEcCtD
Ezetimibe—Anaphylactic shock—Betamethasone—psoriasis	0.000108	0.000561	CcSEcCtD
Ezetimibe—Insomnia—Triamcinolone—psoriasis	0.000107	0.000559	CcSEcCtD
Ezetimibe—Infection—Dexamethasone—psoriasis	0.000107	0.000557	CcSEcCtD
Ezetimibe—Infection—Betamethasone—psoriasis	0.000107	0.000557	CcSEcCtD
Ezetimibe—Ill-defined disorder—Prednisone—psoriasis	0.000107	0.000556	CcSEcCtD
Ezetimibe—Paraesthesia—Triamcinolone—psoriasis	0.000107	0.000555	CcSEcCtD
Ezetimibe—Feeling abnormal—Prednisolone—psoriasis	0.000106	0.000554	CcSEcCtD
Ezetimibe—Anaemia—Prednisone—psoriasis	0.000106	0.000553	CcSEcCtD
Ezetimibe—Dyspnoea—Triamcinolone—psoriasis	0.000106	0.000551	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—CAT—psoriasis	0.000106	0.00213	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Betamethasone—psoriasis	0.000106	0.00055	CcSEcCtD
Ezetimibe—Nervous system disorder—Dexamethasone—psoriasis	0.000106	0.00055	CcSEcCtD
Ezetimibe—Thrombocytopenia—Dexamethasone—psoriasis	0.000106	0.000549	CcSEcCtD
Ezetimibe—Thrombocytopenia—Betamethasone—psoriasis	0.000106	0.000549	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000105	0.00212	CbGpPWpGaD
Ezetimibe—Angioedema—Prednisone—psoriasis	0.000105	0.000547	CcSEcCtD
Ezetimibe—Hypersensitivity—Cyclosporine—psoriasis	0.000105	0.000544	CcSEcCtD
Ezetimibe—Dyspepsia—Triamcinolone—psoriasis	0.000105	0.000544	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—psoriasis	0.000104	0.000543	CcSEcCtD
Ezetimibe—Nausea—Mycophenolic acid—psoriasis	0.000104	0.000543	CcSEcCtD
Ezetimibe—Feeling abnormal—Hydrocortisone—psoriasis	0.000104	0.000541	CcSEcCtD
Ezetimibe—Malaise—Prednisone—psoriasis	0.000104	0.00054	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000103	0.000537	CcSEcCtD
Ezetimibe—Urticaria—Prednisolone—psoriasis	0.000103	0.000534	CcSEcCtD
Ezetimibe—Fatigue—Triamcinolone—psoriasis	0.000102	0.000533	CcSEcCtD
Ezetimibe—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000102	0.000531	CcSEcCtD
Ezetimibe—Asthenia—Cyclosporine—psoriasis	0.000102	0.00053	CcSEcCtD
Ezetimibe—Pain—Triamcinolone—psoriasis	0.000102	0.000529	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000101	0.00203	CbGpPWpGaD
Ezetimibe—Pruritus—Cyclosporine—psoriasis	0.0001	0.000523	CcSEcCtD
Ezetimibe—Urticaria—Hydrocortisone—psoriasis	0.0001	0.000522	CcSEcCtD
Ezetimibe—Angiopathy—Methotrexate—psoriasis	0.0001	0.000521	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—psoriasis	9.97e-05	0.000519	CcSEcCtD
Ezetimibe—Body temperature increased—Hydrocortisone—psoriasis	9.97e-05	0.000519	CcSEcCtD
Ezetimibe—Abdominal pain—Hydrocortisone—psoriasis	9.97e-05	0.000519	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—psoriasis	9.95e-05	0.000518	CcSEcCtD
Ezetimibe—Asthenia—Mycophenolate mofetil—psoriasis	9.94e-05	0.000517	CcSEcCtD
Ezetimibe—Hypertension—Prednisone—psoriasis	9.93e-05	0.000517	CcSEcCtD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	9.84e-05	0.00198	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Betamethasone—psoriasis	9.82e-05	0.000511	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Dexamethasone—psoriasis	9.82e-05	0.000511	CcSEcCtD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.81e-05	0.00197	CbGpPWpGaD
Ezetimibe—Pruritus—Mycophenolate mofetil—psoriasis	9.8e-05	0.00051	CcSEcCtD
Ezetimibe—Myalgia—Prednisone—psoriasis	9.79e-05	0.00051	CcSEcCtD
Ezetimibe—Arthralgia—Prednisone—psoriasis	9.79e-05	0.00051	CcSEcCtD
Ezetimibe—Feeling abnormal—Triamcinolone—psoriasis	9.79e-05	0.00051	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—psoriasis	9.76e-05	0.000508	CcSEcCtD
Ezetimibe—Insomnia—Dexamethasone—psoriasis	9.75e-05	0.000507	CcSEcCtD
Ezetimibe—Insomnia—Betamethasone—psoriasis	9.75e-05	0.000507	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	9.72e-05	0.000506	CcSEcCtD
Ezetimibe—Diarrhoea—Cyclosporine—psoriasis	9.71e-05	0.000506	CcSEcCtD
Ezetimibe—Paraesthesia—Betamethasone—psoriasis	9.68e-05	0.000504	CcSEcCtD
Ezetimibe—Paraesthesia—Dexamethasone—psoriasis	9.68e-05	0.000504	CcSEcCtD
Ezetimibe—Discomfort—Prednisone—psoriasis	9.67e-05	0.000504	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—psoriasis	9.67e-05	0.000504	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—psoriasis	9.61e-05	0.0005	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—psoriasis	9.61e-05	0.0005	CcSEcCtD
Ezetimibe—Hypersensitivity—Prednisolone—psoriasis	9.52e-05	0.000495	CcSEcCtD
Ezetimibe—Dyspepsia—Betamethasone—psoriasis	9.49e-05	0.000494	CcSEcCtD
Ezetimibe—Dyspepsia—Dexamethasone—psoriasis	9.49e-05	0.000494	CcSEcCtD
Ezetimibe—Diarrhoea—Mycophenolate mofetil—psoriasis	9.47e-05	0.000493	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—NDUFA5—psoriasis	9.47e-05	0.00191	CbGpPWpGaD
Ezetimibe—Urticaria—Triamcinolone—psoriasis	9.44e-05	0.000491	CcSEcCtD
Ezetimibe—Body temperature increased—Triamcinolone—psoriasis	9.39e-05	0.000489	CcSEcCtD
Ezetimibe—Dizziness—Cyclosporine—psoriasis	9.39e-05	0.000489	CcSEcCtD
Ezetimibe—Anaphylactic shock—Prednisone—psoriasis	9.39e-05	0.000489	CcSEcCtD
Ezetimibe—Decreased appetite—Betamethasone—psoriasis	9.37e-05	0.000488	CcSEcCtD
Ezetimibe—Decreased appetite—Dexamethasone—psoriasis	9.37e-05	0.000488	CcSEcCtD
Ezetimibe—Infection—Prednisone—psoriasis	9.33e-05	0.000485	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Dexamethasone—psoriasis	9.31e-05	0.000484	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Betamethasone—psoriasis	9.31e-05	0.000484	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—psoriasis	9.3e-05	0.000484	CcSEcCtD
Ezetimibe—Hypersensitivity—Hydrocortisone—psoriasis	9.3e-05	0.000484	CcSEcCtD
Ezetimibe—Fatigue—Betamethasone—psoriasis	9.29e-05	0.000484	CcSEcCtD
Ezetimibe—Fatigue—Dexamethasone—psoriasis	9.29e-05	0.000484	CcSEcCtD
Ezetimibe—Pain—Betamethasone—psoriasis	9.22e-05	0.00048	CcSEcCtD
Ezetimibe—Pain—Dexamethasone—psoriasis	9.22e-05	0.00048	CcSEcCtD
Ezetimibe—Nervous system disorder—Prednisone—psoriasis	9.21e-05	0.000479	CcSEcCtD
Ezetimibe—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.19e-05	0.00185	CbGpPWpGaD
Ezetimibe—Dizziness—Mycophenolate mofetil—psoriasis	9.16e-05	0.000477	CcSEcCtD
Ezetimibe—Skin disorder—Prednisone—psoriasis	9.12e-05	0.000475	CcSEcCtD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.07e-05	0.00183	CbGpPWpGaD
Ezetimibe—Asthenia—Hydrocortisone—psoriasis	9.05e-05	0.000471	CcSEcCtD
Ezetimibe—Vomiting—Cyclosporine—psoriasis	9.03e-05	0.00047	CcSEcCtD
Ezetimibe—Rash—Cyclosporine—psoriasis	8.95e-05	0.000466	CcSEcCtD
Ezetimibe—Dermatitis—Cyclosporine—psoriasis	8.94e-05	0.000465	CcSEcCtD
Ezetimibe—Pruritus—Hydrocortisone—psoriasis	8.93e-05	0.000465	CcSEcCtD
Ezetimibe—Ill-defined disorder—Methotrexate—psoriasis	8.92e-05	0.000464	CcSEcCtD
Ezetimibe—Headache—Cyclosporine—psoriasis	8.89e-05	0.000463	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—psoriasis	8.88e-05	0.000462	CcSEcCtD
Ezetimibe—Feeling abnormal—Betamethasone—psoriasis	8.88e-05	0.000462	CcSEcCtD
Ezetimibe—Feeling abnormal—Dexamethasone—psoriasis	8.88e-05	0.000462	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Betamethasone—psoriasis	8.81e-05	0.000459	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Dexamethasone—psoriasis	8.81e-05	0.000459	CcSEcCtD
Ezetimibe—Vomiting—Mycophenolate mofetil—psoriasis	8.8e-05	0.000458	CcSEcCtD
Ezetimibe—Hypersensitivity—Triamcinolone—psoriasis	8.75e-05	0.000456	CcSEcCtD
Ezetimibe—Rash—Mycophenolate mofetil—psoriasis	8.73e-05	0.000455	CcSEcCtD
Ezetimibe—Dermatitis—Mycophenolate mofetil—psoriasis	8.72e-05	0.000454	CcSEcCtD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.72e-05	0.00175	CbGpPWpGaD
Ezetimibe—Headache—Mycophenolate mofetil—psoriasis	8.68e-05	0.000452	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—psoriasis	8.67e-05	0.000451	CcSEcCtD
Ezetimibe—Diarrhoea—Hydrocortisone—psoriasis	8.63e-05	0.000449	CcSEcCtD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	8.56e-05	0.00172	CbGpPWpGaD
Ezetimibe—Urticaria—Betamethasone—psoriasis	8.56e-05	0.000446	CcSEcCtD
Ezetimibe—Urticaria—Dexamethasone—psoriasis	8.56e-05	0.000446	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Prednisone—psoriasis	8.55e-05	0.000445	CcSEcCtD
Ezetimibe—Dizziness—Prednisolone—psoriasis	8.54e-05	0.000445	CcSEcCtD
Ezetimibe—Asthenia—Triamcinolone—psoriasis	8.52e-05	0.000444	CcSEcCtD
Ezetimibe—Body temperature increased—Betamethasone—psoriasis	8.52e-05	0.000444	CcSEcCtD
Ezetimibe—Abdominal pain—Betamethasone—psoriasis	8.52e-05	0.000444	CcSEcCtD
Ezetimibe—Body temperature increased—Dexamethasone—psoriasis	8.52e-05	0.000444	CcSEcCtD
Ezetimibe—Abdominal pain—Dexamethasone—psoriasis	8.52e-05	0.000444	CcSEcCtD
Ezetimibe—Insomnia—Prednisone—psoriasis	8.49e-05	0.000442	CcSEcCtD
Ezetimibe—Nausea—Cyclosporine—psoriasis	8.43e-05	0.000439	CcSEcCtD
Ezetimibe—Paraesthesia—Prednisone—psoriasis	8.43e-05	0.000439	CcSEcCtD
Ezetimibe—Pruritus—Triamcinolone—psoriasis	8.4e-05	0.000437	CcSEcCtD
Ezetimibe—Cough—Methotrexate—psoriasis	8.39e-05	0.000437	CcSEcCtD
Ezetimibe—Dizziness—Hydrocortisone—psoriasis	8.34e-05	0.000434	CcSEcCtD
Ezetimibe—Dyspepsia—Prednisone—psoriasis	8.26e-05	0.00043	CcSEcCtD
Ezetimibe—Nausea—Mycophenolate mofetil—psoriasis	8.23e-05	0.000428	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—APOE—psoriasis	8.22e-05	0.00165	CbGpPWpGaD
Ezetimibe—Arthralgia—Methotrexate—psoriasis	8.18e-05	0.000426	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—psoriasis	8.18e-05	0.000426	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—psoriasis	8.18e-05	0.000426	CcSEcCtD
Ezetimibe—Decreased appetite—Prednisone—psoriasis	8.16e-05	0.000425	CcSEcCtD
Ezetimibe—Rash—Prednisolone—psoriasis	8.14e-05	0.000424	CcSEcCtD
Ezetimibe—Dermatitis—Prednisolone—psoriasis	8.14e-05	0.000424	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.13e-05	0.000423	CcSEcCtD
Ezetimibe—Fatigue—Prednisone—psoriasis	8.09e-05	0.000421	CcSEcCtD
Ezetimibe—Headache—Prednisolone—psoriasis	8.09e-05	0.000421	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—psoriasis	8.09e-05	0.000421	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—CYP2S1—psoriasis	8.05e-05	0.00162	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—NDUFA5—psoriasis	8.05e-05	0.00162	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NDUFA5—psoriasis	8.05e-05	0.00162	CbGpPWpGaD
Ezetimibe—Constipation—Prednisone—psoriasis	8.03e-05	0.000418	CcSEcCtD
Ezetimibe—Vomiting—Hydrocortisone—psoriasis	8.02e-05	0.000418	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—CAT—psoriasis	8.02e-05	0.00161	CbGpPWpGaD
Ezetimibe—Rash—Hydrocortisone—psoriasis	7.95e-05	0.000414	CcSEcCtD
Ezetimibe—Dermatitis—Hydrocortisone—psoriasis	7.95e-05	0.000414	CcSEcCtD
Ezetimibe—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.93e-05	0.0016	CbGpPWpGaD
Ezetimibe—Confusional state—Methotrexate—psoriasis	7.91e-05	0.000412	CcSEcCtD
Ezetimibe—Headache—Hydrocortisone—psoriasis	7.9e-05	0.000411	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL10—psoriasis	7.89e-05	0.00159	CbGpPWpGaD
Ezetimibe—Dizziness—Triamcinolone—psoriasis	7.86e-05	0.000409	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methotrexate—psoriasis	7.84e-05	0.000408	CcSEcCtD
Ezetimibe—Infection—Methotrexate—psoriasis	7.79e-05	0.000406	CcSEcCtD
Ezetimibe—Feeling abnormal—Prednisone—psoriasis	7.74e-05	0.000403	CcSEcCtD
Ezetimibe—Asthenia—Betamethasone—psoriasis	7.73e-05	0.000403	CcSEcCtD
Ezetimibe—Asthenia—Dexamethasone—psoriasis	7.73e-05	0.000403	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—CAT—psoriasis	7.72e-05	0.00155	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Methotrexate—psoriasis	7.69e-05	0.0004	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—psoriasis	7.68e-05	0.0004	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Prednisone—psoriasis	7.68e-05	0.0004	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL4—psoriasis	7.67e-05	0.00154	CbGpPWpGaD
Ezetimibe—Nausea—Prednisolone—psoriasis	7.67e-05	0.000399	CcSEcCtD
Ezetimibe—Pruritus—Betamethasone—psoriasis	7.63e-05	0.000397	CcSEcCtD
Ezetimibe—Pruritus—Dexamethasone—psoriasis	7.63e-05	0.000397	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—psoriasis	7.62e-05	0.000397	CcSEcCtD
Ezetimibe—Vomiting—Triamcinolone—psoriasis	7.55e-05	0.000393	CcSEcCtD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.51e-05	0.00151	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.5e-05	0.00151	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.49e-05	0.00151	CbGpPWpGaD
Ezetimibe—Nausea—Hydrocortisone—psoriasis	7.49e-05	0.00039	CcSEcCtD
Ezetimibe—Rash—Triamcinolone—psoriasis	7.49e-05	0.00039	CcSEcCtD
Ezetimibe—Dermatitis—Triamcinolone—psoriasis	7.48e-05	0.00039	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	7.48e-05	0.00151	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.48e-05	0.00151	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—CXCL8—psoriasis	7.47e-05	0.0015	CbGpPWpGaD
Ezetimibe—Urticaria—Prednisone—psoriasis	7.46e-05	0.000388	CcSEcCtD
Ezetimibe—Headache—Triamcinolone—psoriasis	7.44e-05	0.000387	CcSEcCtD
Ezetimibe—Body temperature increased—Prednisone—psoriasis	7.42e-05	0.000386	CcSEcCtD
Ezetimibe—Abdominal pain—Prednisone—psoriasis	7.42e-05	0.000386	CcSEcCtD
Ezetimibe—Diarrhoea—Betamethasone—psoriasis	7.37e-05	0.000384	CcSEcCtD
Ezetimibe—Diarrhoea—Dexamethasone—psoriasis	7.37e-05	0.000384	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—CARM1—psoriasis	7.34e-05	0.00148	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PPARG—psoriasis	7.16e-05	0.00144	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—psoriasis	7.15e-05	0.000372	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	7.14e-05	0.00144	CbGpPWpGaD
Ezetimibe—Dizziness—Dexamethasone—psoriasis	7.13e-05	0.000371	CcSEcCtD
Ezetimibe—Dizziness—Betamethasone—psoriasis	7.13e-05	0.000371	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—psoriasis	7.1e-05	0.000369	CcSEcCtD
Ezetimibe—Nausea—Triamcinolone—psoriasis	7.06e-05	0.000367	CcSEcCtD
Ezetimibe—Paraesthesia—Methotrexate—psoriasis	7.04e-05	0.000367	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—psoriasis	6.99e-05	0.000364	CcSEcCtD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.98e-05	0.00141	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.95e-05	0.0014	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Prednisone—psoriasis	6.92e-05	0.00036	CcSEcCtD
Ezetimibe—Dyspepsia—Methotrexate—psoriasis	6.91e-05	0.000359	CcSEcCtD
Ezetimibe—Vomiting—Dexamethasone—psoriasis	6.85e-05	0.000357	CcSEcCtD
Ezetimibe—Vomiting—Betamethasone—psoriasis	6.85e-05	0.000357	CcSEcCtD
Ezetimibe—ABCC3—Metabolism—CYP2S1—psoriasis	6.85e-05	0.00138	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP2S1—psoriasis	6.85e-05	0.00138	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.84e-05	0.00138	CbGpPWpGaD
Ezetimibe—Decreased appetite—Methotrexate—psoriasis	6.82e-05	0.000355	CcSEcCtD
Ezetimibe—Rash—Betamethasone—psoriasis	6.8e-05	0.000354	CcSEcCtD
Ezetimibe—Rash—Dexamethasone—psoriasis	6.8e-05	0.000354	CcSEcCtD
Ezetimibe—Dermatitis—Dexamethasone—psoriasis	6.79e-05	0.000353	CcSEcCtD
Ezetimibe—Dermatitis—Betamethasone—psoriasis	6.79e-05	0.000353	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—psoriasis	6.77e-05	0.000353	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—psoriasis	6.76e-05	0.000352	CcSEcCtD
Ezetimibe—Headache—Betamethasone—psoriasis	6.75e-05	0.000351	CcSEcCtD
Ezetimibe—Headache—Dexamethasone—psoriasis	6.75e-05	0.000351	CcSEcCtD
Ezetimibe—Asthenia—Prednisone—psoriasis	6.73e-05	0.000351	CcSEcCtD
Ezetimibe—Pain—Methotrexate—psoriasis	6.71e-05	0.000349	CcSEcCtD
Ezetimibe—Pruritus—Prednisone—psoriasis	6.64e-05	0.000346	CcSEcCtD
Ezetimibe—UGT1A1—Metabolism—NDUFA5—psoriasis	6.54e-05	0.00132	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Methotrexate—psoriasis	6.46e-05	0.000337	CcSEcCtD
Ezetimibe—Diarrhoea—Prednisone—psoriasis	6.42e-05	0.000334	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—psoriasis	6.41e-05	0.000334	CcSEcCtD
Ezetimibe—Nausea—Dexamethasone—psoriasis	6.4e-05	0.000333	CcSEcCtD
Ezetimibe—Nausea—Betamethasone—psoriasis	6.4e-05	0.000333	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.35e-05	0.00128	CbGpPWpGaD
Ezetimibe—Urticaria—Methotrexate—psoriasis	6.23e-05	0.000324	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—APOE—psoriasis	6.23e-05	0.00125	CbGpPWpGaD
Ezetimibe—Dizziness—Prednisone—psoriasis	6.21e-05	0.000323	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—psoriasis	6.2e-05	0.000323	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—psoriasis	6.2e-05	0.000323	CcSEcCtD
Ezetimibe—SLCO1B1—Metabolism—NDUFA5—psoriasis	6e-05	0.00121	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—APOE—psoriasis	6e-05	0.00121	CbGpPWpGaD
Ezetimibe—Vomiting—Prednisone—psoriasis	5.97e-05	0.000311	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	5.93e-05	0.00119	CbGpPWpGaD
Ezetimibe—Rash—Prednisone—psoriasis	5.92e-05	0.000308	CcSEcCtD
Ezetimibe—Dermatitis—Prednisone—psoriasis	5.91e-05	0.000308	CcSEcCtD
Ezetimibe—Headache—Prednisone—psoriasis	5.88e-05	0.000306	CcSEcCtD
Ezetimibe—Hypersensitivity—Methotrexate—psoriasis	5.78e-05	0.000301	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	5.66e-05	0.00114	CbGpPWpGaD
Ezetimibe—Asthenia—Methotrexate—psoriasis	5.63e-05	0.000293	CcSEcCtD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.59e-05	0.00113	CbGpPWpGaD
Ezetimibe—Nausea—Prednisone—psoriasis	5.58e-05	0.00029	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	5.57e-05	0.00112	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP2S1—psoriasis	5.56e-05	0.00112	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NDUFA5—psoriasis	5.55e-05	0.00112	CbGpPWpGaD
Ezetimibe—Pruritus—Methotrexate—psoriasis	5.55e-05	0.000289	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—PPARG—psoriasis	5.43e-05	0.00109	CbGpPWpGaD
Ezetimibe—Diarrhoea—Methotrexate—psoriasis	5.37e-05	0.000279	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	5.32e-05	0.00107	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PPARG—psoriasis	5.22e-05	0.00105	CbGpPWpGaD
Ezetimibe—Dizziness—Methotrexate—psoriasis	5.19e-05	0.00027	CcSEcCtD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	5.16e-05	0.00104	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP2S1—psoriasis	5.1e-05	0.00103	CbGpPWpGaD
Ezetimibe—Vomiting—Methotrexate—psoriasis	4.99e-05	0.00026	CcSEcCtD
Ezetimibe—Rash—Methotrexate—psoriasis	4.95e-05	0.000257	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—psoriasis	4.94e-05	0.000257	CcSEcCtD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.92e-05	0.000991	CbGpPWpGaD
Ezetimibe—Headache—Methotrexate—psoriasis	4.91e-05	0.000256	CcSEcCtD
Ezetimibe—ABCG2—Metabolism—CYP2S1—psoriasis	4.72e-05	0.00095	CbGpPWpGaD
Ezetimibe—Nausea—Methotrexate—psoriasis	4.66e-05	0.000243	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IFNG—psoriasis	4.64e-05	0.000934	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.63e-05	0.000932	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CAT—psoriasis	4.52e-05	0.000909	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.31e-05	0.000868	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.05e-05	0.000814	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CARM1—psoriasis	3.93e-05	0.000791	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.59e-05	0.000722	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.55e-05	0.000715	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—APOE—psoriasis	3.51e-05	0.000706	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.5e-05	0.000705	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CARM1—psoriasis	3.34e-05	0.000673	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CARM1—psoriasis	3.34e-05	0.000673	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.13e-05	0.000629	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PPARG—psoriasis	3.06e-05	0.000615	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TNF—psoriasis	3e-05	0.000604	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NDUFA5—psoriasis	3e-05	0.000604	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.98e-05	0.000601	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.79e-05	0.000561	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CARM1—psoriasis	2.72e-05	0.000547	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.67e-05	0.000538	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.66e-05	0.000536	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP2S1—psoriasis	2.55e-05	0.000514	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CARM1—psoriasis	2.49e-05	0.000501	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CAT—psoriasis	2.42e-05	0.000487	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.33e-05	0.000468	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CARM1—psoriasis	2.31e-05	0.000464	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CAT—psoriasis	2.06e-05	0.000414	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CAT—psoriasis	2.06e-05	0.000414	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.98e-05	0.000398	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.9e-05	0.000383	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—APOE—psoriasis	1.88e-05	0.000378	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NDUFA5—psoriasis	1.85e-05	0.000372	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.73e-05	0.000348	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CAT—psoriasis	1.67e-05	0.000336	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARG—psoriasis	1.64e-05	0.000329	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—APOE—psoriasis	1.6e-05	0.000322	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—APOE—psoriasis	1.6e-05	0.000322	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP2S1—psoriasis	1.57e-05	0.000316	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CAT—psoriasis	1.53e-05	0.000308	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.48e-05	0.000298	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CAT—psoriasis	1.42e-05	0.000285	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARG—psoriasis	1.39e-05	0.00028	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARG—psoriasis	1.39e-05	0.00028	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.31e-05	0.000263	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—APOE—psoriasis	1.3e-05	0.000261	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CARM1—psoriasis	1.25e-05	0.000251	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—APOE—psoriasis	1.19e-05	0.000239	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARG—psoriasis	1.13e-05	0.000228	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—APOE—psoriasis	1.1e-05	0.000222	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARG—psoriasis	1.04e-05	0.000209	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARG—psoriasis	9.6e-06	0.000193	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CARM1—psoriasis	7.68e-06	0.000155	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CAT—psoriasis	7.67e-06	0.000154	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—APOE—psoriasis	5.96e-06	0.00012	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARG—psoriasis	5.19e-06	0.000104	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CAT—psoriasis	4.72e-06	9.51e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—APOE—psoriasis	3.67e-06	7.39e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARG—psoriasis	3.2e-06	6.43e-05	CbGpPWpGaD
